5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis (Q35055982)

6 August 2017

0 references

5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis (English)

1 reference

6 August 2017

1 reference

Zacharias G Laoutidis

series ordinal

1

1 reference

6 August 2017

Christian Luckhaus

series ordinal

2

1 reference

6 August 2017

language of work or name

1 reference

29 November 2013

1 reference

The International Journal of Neuropsychopharmacology

6 August 2017

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

823-832

1 reference

Atenolol and propranolol in neuroleptic-induced akathisia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Acute antipsychotic-induced akathisia revisited

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Consciousness still a mystery

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Risk factors for the development of neuroleptic induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Vitamin B6 Treatment for Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Vitamin B6 Treatment in Acute Neuroleptic-Induced Akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Rediscovering trazodone for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Akathisia and suicidal ideation in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Low-dose apomorphine challenge in tardive akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

Motor disorders induced by neuroleptics: a proposed new classification.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001417

7 January 2021

10.1017/S1461145713001417

Identifiers

DOI

1 reference

6 August 2017

1 reference